Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549196 · ClinicalTrials.gov registry record · Phase 2
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
A Phase 2 study of Dementia of Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT02549196: Completed Phase 2 study of Dementia of Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
NCT02549196 is a Phase 2 study of Dementia of Alzheimer's Type that has completed, run by Chase Pharmaceuticals Corporation, an affiliate of Allergan. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02549196, a Phase 2 study of Dementia of Alzheimer's Type, has completed, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
Primary Outcome
Of the four cohorts with different dosing schedules for CPC-201, the cohort with the greatest proportion of participants to reach the donepezil MAD was determined to be the optimal administration regimen.
Conditions Studied
Interventions
- DRUG Donepezil
- DRUG Solifenacin
Study Locations (4)
Florida
- Quantum Laboratories - Deerfield Beach
- Miami Jewish Health Systems - Miami
- Premiere Research Institute - West Palm Beach
North Carolina
- PMG Research - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2017-09-28 |
| Phase | Phase 2 |
What the finished NCT02549196 record still lists
NCT02549196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Dementia of Alzheimer's Type appearing as the primary indexed condition, and to 2 interventions - of which Donepezil is the first listed.
NCT02549196 reports a single indexed study location in Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02549196 about?
NCT02549196 is a clinical study titled "A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type". This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
What is the current status of trial NCT02549196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2015-10-07. Estimated completion is 2017-09-28.
What conditions does trial NCT02549196 study?
This clinical trial studies the following conditions: Dementia of Alzheimer's Type.
What interventions are being tested in trial NCT02549196?
The interventions under investigation include: Donepezil (DRUG), Solifenacin (DRUG).
Who is sponsoring clinical trial NCT02549196?
This trial is sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02549196 being conducted?
This trial has 4 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02549196's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI